Selective inhibition of K-Ras G12C through allosteric control of GTP affinity and effector interactions

被引：0
|
作者：
Ostrem, Jonathan M. [1 ]
Peters, Ulf [1 ]
Sos, Martin L. [1 ]
Wells, James A. [2 ]
Shokat, Kevan M. [1 ]
机构：
[1] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-PL04-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PL04-03
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Novel therapeutic strategy for KRAS G12C mutant NSCLC with combination of KRAS-GTP and mTORC1 kinase inhibition
    Kitai, Hidenori
    CANCER SCIENCE, 2025, 116 : 1289 - 1289
  • [42] Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK
    Coma, Silvia
    Chowdhury, Sanjib
    Dilly, Julien
    Musteanu, Monica
    Barbacid, Mariano
    Aguirre, Andrew J.
    Pachter, Jonathan A.
    CANCER RESEARCH, 2022, 82 (12)
  • [43] IMPROVED GROWTH PROPERTIES AND IMMUNE SURVEILLANCE IN K-RAS G12V-TRANSFORMED CELLS THROUGH OVEREXPRESSION OF BIGLYCAN
    Subbarayan, Karthikeyan
    Leisz, Sandra
    Massa, Chiara
    Balina, Sravankumar
    Mueller, Anja
    Wickenhauser, Claudia
    Seliger, Barbara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A495 - A496
  • [44] K-Ras Peptide Mimotope Induces Antigen Specific Th1 and B-Cell Immune Responses against G12A-Mutated K-Ras Antigen in Balb/c Mice
    Siak, Pui Yan
    Wong, Kuan Yee
    Song, Adelene Ai-Lian
    Rahim, Raha Abdul
    In, Lionel Lian Aun
    VACCINES, 2021, 9 (03) : 1 - 18
  • [45] KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
    Misale, Sandra
    Fatherree, Jackson P.
    Cortez, Eliane
    Li, Chendi
    Bilton, Samantha
    Timonina, Daria
    Myers, David T.
    Lee, Dana
    Gomez-Caraballo, Maria
    Greenberg, Max
    Nangia, Varuna
    Greninger, Patricia
    Egan, Regina K.
    McClanaghan, Joseph
    Stein, Giovanna T.
    Murchie, Ellen
    Zarrinkar, Patrick P.
    Janes, Matthew R.
    Li, Lian-Sheng
    Liu, Yi
    Hata, Aaron N.
    Benes, Cyril H.
    CLINICAL CANCER RESEARCH, 2019, 25 (02) : 796 - 807
  • [46] K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
    Sakamoto, Kotaro
    Kamada, Yusuke
    Sameshima, Tomoya
    Yaguchi, Masahiro
    Niida, Ayumu
    Sasaki, Shigekazu
    Miwa, Masanori
    Ohkubo, Shoichi
    Sakamoto, Jun-ichi
    Kamaura, Masahiro
    Cho, Nobuo
    Tani, Akiyoshi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 484 (03) : 605 - 611
  • [47] Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
    Rosell, R.
    Gomez-Vazquez, J. L.
    Lewintre, E. Jantus
    Ito, M.
    Cao, P.
    Cai, X.
    Xing, B.
    Farinas, S. Calabuig
    Cardona, A. F.
    Rodriguez, J. K.
    Jordan, M. Marco
    Valdunciel, C. Pedraz
    Molina-Vila, M. A.
    Codony-Servat, J.
    Dantes, Z.
    Aguilar, A.
    Sullivan, I. G.
    Horno, I. Moya
    Cirera, L.
    Gonzalez-Cao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S149 - S149
  • [48] KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
    Patel, H.
    Chan, S.
    Smith, A.
    Burrows, F.
    Malik, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S146
  • [49] PI3K pathway inhibition induces a different metabolic response in NSCLC cells harboring and G12C mutant KRAS
    Caiola, Elisa
    Brunelli, Laura
    Marabese, Mirko
    Pastorelli, Roberta
    Lupi, Monica
    Broggini, Massimo
    CANCER RESEARCH, 2016, 76
  • [50] KRAS G12C colon cancer resistance to vertical MAPK inhibition converges on FOS-JUN signaling through orthogonal mechanisms
    Koleilat, Mohamad Karim
    Kwong, Lawrence
    CANCER RESEARCH, 2023, 83 (07)
12345